Biomaterial‐Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives

O’Neill, Hugh; Gallagher, Laura; O’Sullivan, Janice; Whyte, William; Curley, Clive J.; Duffy, Garry P.; Hameed, Aamir; O’Dwyer, Joanne; Payne, Christina; O’Reilly, Daniel; Ruiz, José; Roche, Ellen T.; O’Brien, Fergal J.; Cryan, Sally‐Ann; Kelly, Helena; Murphy, Bruce P.

doi:10.1002/adma.201505349

Cited by 62 publications

(50 citation statements)

References 127 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, the use of biomaterials injected directly into the heart muscle (myocardium) to prevent or attenuate adverse post‐MI remodeling has become a viable therapy and an area of growing research focus. Minimally invasive devices have been developed for delivering biomaterials through the endocardium or the epicardium, and studies have used a range of hydrogels in preclinical and clinical experiments, demonstrating an ability to decrease stress in the myocardial wall by modifying the mechanical properties and increasing wall thickness. These studies indicate that the mechanical reinforcement provided by the injected biomaterial can prevent MI progression …”

Section: Introductionmentioning

confidence: 99%

A comparison of two quasi‐static computational models for assessment of intra‐myocardial injection as a therapeutic strategy for heart failure

Fan

Ronan

Teh

et al. 2019

Numer Methods Biomed Eng

Self Cite

View full text Add to dashboard Cite

Myocardial infarction, or heart attack, is the leading cause of mortality globally. Although the treatment of myocardial infarct has improved significantly, scar tissue that persists can often lead to increased stress and adverse remodeling of surrounding tissue and ultimately to heart failure. Intra‐myocardial injection of biomaterials represents a potential treatment to attenuate remodeling, mitigate degeneration, and reverse the disease process in the tissue. In vivo experiments on animal models have shown functional benefits of this therapeutic strategy. However, a poor understanding of the optimal injection pattern, volume, and material properties has acted as a barrier to its widespread clinical adoption. In this study, we developed two quasistatic finite element simulations of the left ventricle to investigate the mechanical effect of intra‐myocardial injection. The first model employed an idealized left ventricular geometry with rule‐based cardiomyocyte orientation. The second model employed a subject‐specific left ventricular geometry with cardiomyocyte orientation from diffusion tensor magnetic resonance imaging. Both models predicted cardiac parameters including ejection fraction, systolic wall thickening, and ventricular twist that matched experimentally reported values. All injection simulations showed cardiomyocyte stress attenuation, offering an explanation for the mechanical reinforcement benefit associated with injection. The study also enabled a comparison of injection location and the corresponding effect on cardiac performance at different stages of the cardiac cycle. While the idealized model has lower fidelity, it predicts cardiac function and differentiates the effects of injection location. Both models represent versatile in silico tools to guide optimal strategy in terms of injection number, volume, site, and material properties.

show abstract

Section: Introductionmentioning

confidence: 99%

A comparison of two quasi‐static computational models for assessment of intra‐myocardial injection as a therapeutic strategy for heart failure

Fan

Ronan

Teh

et al. 2019

Numer Methods Biomed Eng

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hydrogels are promising materials for manufacturing tissue engineered scaffolds (Suo, Xu, & Zheng, 2015;Yan et al, 2016), and high porosity of hydrogels permits loading of specific drugs into the gel matrix, while the drugs can be subsequently released in situ at a rate depending on the diffusion of the small molecules or macromolecules through the gel network (Chung & Burdick, 2008;Hoare & Kohane, 2008). In previous studies, various types of hydrogels such as polyethylene glycol (PEG), gelatin, alginate, hyaluronic acid, and chitosan have been employed in drug delivery (Anirudhan, Divya, & Nima, 2016;O'Neill et al, 2016;Ye et al, 2016). Among these materials, gelatin is the product of collagen hydrolysis, which is the main component of cartilage matrix (Nichol, Koshy, Bae, Hwang, Yamanlar, & Khademhosseini, 2010).…”

mentioning

confidence: 99%

Glucosamine‐grafted methacrylated gelatin hydrogels as potential biomaterials for cartilage repair

Suo

Zhang

et al. 2019

J Biomed Mater Res

View full text Add to dashboard Cite

Glucosamine (GlcN) has been widely used to reduce joint pain and osteoarthritis progression, but the efficacy of GlcN remains controversial because of the low GlcN concentration reaching the articular cavity. The aim of this study is to provide an effective approach of GlcN delivery to a target site using photocrosslinkable methacrylated gelatin (GelMA)‐based hydrogels, where GlcN could be gradually released during the degradation of the GelMA hydrogel. Herein, GlcN was acrylated as the acryloyl glucosamine (AGA) and covalently grafted to GelMA, and more than 87.7% of 15% (w/v) GelMA hydrogel was grafted with AGA. Moreover, in vitro outgrowth and apoptosis assay of bone marrow stem cells (BMSCs) demonstrated that the GelMA–AGA hydrogels had better biocompatibility, larger cell attachment, and higher cell viability than pure GlcN and AGA materials. Also, 15% (w/v) GelMA–AGA hydrogel was injected into the defect site for in vivo rabbit cartilage repair. Compared with oral administration of pure GlcN and injection of pure GelMA, the repaired cartilages using GelMA–AGA hydrogels had the smoothest surface of the defect site, filling more than 95% defect bulk. The similar content of glycosaminoglycans to the native tissue and the maximum amount of type II collagen was found in the repaired cartilage using GelMA–AGA hydrogels, indicating the outgrowth of hyaline cartilage.

show abstract

“…Preclinical studies have shown poor engraftment and survival of cells that are directly administered only in saline or media, due to their immediate encounter with harsh conditions such as hypoxia, inflammation, and reactive oxygen species [107]. Biomaterials can function as a substitute to native ECM, conferring a conducive framework for the attachment and growth of encapsulated cells, and thereby preventing anoikis, a form of apoptosis.…”

Section: Biomaterials For Controlled Deliverymentioning

confidence: 99%

Biomaterials for Craniofacial Bone Regeneration

Thrivikraman

Athirasala

Twohig

et al. 2017

Dental Clinics of North America

104

View full text Add to dashboard Cite

Synopsis Functional reconstruction of craniofacial defects is a major clinical challenge in craniofacial sciences, especially in complex situations involving traumatic injury, cranioplasty and oncologic surgery. The advent of biomaterials has been viewed as a potential alternative to standard autologous/allogenic grafting procedures to achieve clinically successful bone regeneration. Over the years, the field of biomaterials for bone augmentation has swiftly advanced to create novel instructive materials and engineering technologies, emerging as an important therapeutic modality for craniofacial regeneration. This chapter discusses various classes of biomaterials, ranging from bioceramics to biopolymers that are currently employed in craniofacial reconstruction. Further, here we review the clinical applications of biomaterials as delivery agents for the sustained release of stem cells, genes and growth factors. Additionally, we cover recent advancements in 3D printing and bioprinting techniques that appear to be promising for future clinical treatments for craniofacial reconstruction. In summary, the present review highlights relevant topics in the bone regeneration literature exemplifying the potential of biomaterials to repair bone defects.

show abstract

Biomaterial‐Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives

Cited by 62 publications

References 127 publications

A comparison of two quasi‐static computational models for assessment of intra‐myocardial injection as a therapeutic strategy for heart failure

A comparison of two quasi‐static computational models for assessment of intra‐myocardial injection as a therapeutic strategy for heart failure

Glucosamine‐grafted methacrylated gelatin hydrogels as potential biomaterials for cartilage repair

Biomaterials for Craniofacial Bone Regeneration

Contact Info

Product

Resources

About